Hints and tips:
Showing results for Intas Pharmaceuticals Limited
Related Special Reports
...Curaleaf is listed on the Toronto Stock Exchange in Canada, which legalised consumption and limited production of cannabis in 2018....
...“Having a broken leg didn’t make me a lesser person, but it did dictate my immediate actions and greatly limited my options in the moment,” the 57-year-old said on Tuesday....
...The practice is currently limited to a small number of companies, including Illumina and Allelica, and its use is not yet widespread....
...An Indian pharmaceutical manufacturer, Intas, is a major supplier of finished dosage methotrexate to the US through its subsidiary Accord Healthcare....
...If treatment facilities are unavailable or unaffordable, the diagnosis may be of limited benefit — and may add to the psychological burden on patients....
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...It already made its diagnostics products in the country but had “limited manufacturing for pharma”, he added....
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...The Association of the British Pharmaceutical Industry, the drugmakers’ trade body, said it supported “this tough deal” even though the agreement would continue to restrict pharmaceutical companies’ sales...
...The pharmaceutical industry is close to agreeing a deal with the UK government over drug pricing, according to the chief financial officer of Swiss drugmaker Novartis....
...But the proposal has run into opposition from the pharmaceutical industry....
...In the UK, Wegovy is available in limited supply on the NHS but patients using private healthcare can pay up to £300 for a month’s supply. Costs are similar in Denmark and Germany....
...In contrast, pharmaceutical companies raised just $160mn for antibiotic research, a decline over the decade. Commercial activity and research in antibiotics have been in decline since the 1980s....
...“So it is particularly important to protect our limited [stock] of effective anti-fungal drugs.”...
...Previously, the functionality of the engineered microbes was limited because their DNA could only be reprogrammed to produce a small number of amino acids — the building blocks of proteins....
...The current draft does not address this and is thus essentially limited to enabling the manufacture of comparatively simple pharmaceutical products, which generally do not require access to information that...
...The cisplatin shortage is linked to quality control problems at a factory in India run by Intas Pharmaceuticals, which provides around half of the US’s entire supply of the chemotherapy drug....
...Discovering this DNA signature of tumours requires whole genome sequencing — reading all 3.2bn letters of genetic code in their DNA — rather than carrying out a more limited panel of genetic tests, which...
If niche treatments are pricey, even using them for limited numbers of patients pays off
...But since this trade was based around importing and ‘hubbing’ out of the UK, it was arguably of limited value for the wider economy anyway....
...Supply shortages are not limited to the UK....
...The order is the latest twist in frantic legal wrangling between anti-abortion campaigners, the US government and the pharmaceutical industry over the regulatory standing of mifepristone....
...The high court on Wednesday agreed to hear an appeal against lower court decisions that limited access to abortion pills containing mifepristone, which account for more than half of abortions in the US....
...They seek to block implementation of reforms that give Medicare — the US taxpayer-funded healthcare scheme for retirees — the ability to negotiate prices for a limited number of branded medicines....
...The Pharmaceutical Research and Manufacturers of America is suing the US over a law that hands the federal government the power to negotiate prices for some of the most expensive drugs....
International Edition